Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) Earnings Analysis
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) next reports earnings on 2026-08-28. It has beaten estimates in 0/2 recent quarters (0%). Trailing P/E 29.81.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 300357.SZ next report earnings?
| Next earnings date | 2026-08-28 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
300357.SZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-27 | 0.23 CNY | n/a | n/a | n/a |
| 2026-04-24 | 0.0689 CNY | n/a | n/a | n/a |
| 2025-10-24 | 0.3206 CNY | n/a | n/a | n/a |
| 2025-04-18 | 0.08703 CNY | 0.15 CNY | -42% | Miss |
| 2025-03-31 | 0.142 CNY | n/a | n/a | n/a |
| 2024-08-22 | 0.1376 CNY | 0.17 CNY | -19.1% | Miss |
Beat rate: 0/2 (0%) over reported quarters with consensus data.
300357.SZ valuation and analyst view
| Trailing P/E | 29.81 |
|---|---|
| Trailing EPS | 0.81322 CNY |
| Price / book | 4.67 |
| Dividend yield | 0.61% |
| Market cap | 12.82B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ)'s next earnings date?
Zhejiang Wolwo Bio-Pharmaceutical is next scheduled to report on 2026-08-28.
Did 300357.SZ beat earnings last quarter?
Consensus estimate data was not available for 300357.SZ's 2026-04-27 report.
What is 300357.SZ's earnings track record?
Over the last 2 reported quarters with consensus data, 300357.SZ beat estimates 0 times (0%).
What is 300357.SZ's current P/E ratio and EPS?
300357.SZ trades at a trailing P/E of 29.81 on trailing EPS of 0.8132180037790374 CNY.
What do analysts rate 300357.SZ?
300357.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.